fujifilm diosynth biotechnologies uk limited
fujifilm diosynth biotechnologies uk limited Company Information
Company Number
05803359
Next Accounts
Dec 2025
Shareholders
fujifilm corporation
Group Structure
View All
Industry
Manufacture of pharmaceutical preparations
+1Registered Address
fujifilm diosynth biotechnologie, belasis avenue, billingham, TS23 1LH
Website
www.fujifilm.comfujifilm diosynth biotechnologies uk limited Estimated Valuation
Pomanda estimates the enterprise value of FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED at £331.1m based on a Turnover of £177.7m and 1.86x industry multiple (adjusted for size and gross margin).
fujifilm diosynth biotechnologies uk limited Estimated Valuation
Pomanda estimates the enterprise value of FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED at £161.5m based on an EBITDA of £21m and a 7.69x industry multiple (adjusted for size and gross margin).
fujifilm diosynth biotechnologies uk limited Estimated Valuation
Pomanda estimates the enterprise value of FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED at £377m based on Net Assets of £201.4m and 1.87x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Fujifilm Diosynth Biotechnologies Uk Limited Overview
Fujifilm Diosynth Biotechnologies Uk Limited is a live company located in billingham, TS23 1LH with a Companies House number of 05803359. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in May 2006, it's largest shareholder is fujifilm corporation with a 100% stake. Fujifilm Diosynth Biotechnologies Uk Limited is a established, mega sized company, Pomanda has estimated its turnover at £177.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Fujifilm Diosynth Biotechnologies Uk Limited Health Check
Pomanda's financial health check has awarded Fujifilm Diosynth Biotechnologies Uk Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 5 areas for improvement. Company Health Check FAQs
5 Strong
2 Regular
5 Weak
Size
annual sales of £177.7m, make it larger than the average company (£20.9m)
£177.7m - Fujifilm Diosynth Biotechnologies Uk Limited
£20.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 14%, show it is growing at a faster rate (8.7%)
14% - Fujifilm Diosynth Biotechnologies Uk Limited
8.7% - Industry AVG
Production
with a gross margin of 13.5%, this company has a higher cost of product (42.7%)
13.5% - Fujifilm Diosynth Biotechnologies Uk Limited
42.7% - Industry AVG
Profitability
an operating margin of 2.1% make it more profitable than the average company (0.8%)
2.1% - Fujifilm Diosynth Biotechnologies Uk Limited
0.8% - Industry AVG
Employees
with 1148 employees, this is above the industry average (69)
1148 - Fujifilm Diosynth Biotechnologies Uk Limited
69 - Industry AVG
Pay Structure
on an average salary of £56.7k, the company has a lower pay structure (£72.3k)
£56.7k - Fujifilm Diosynth Biotechnologies Uk Limited
£72.3k - Industry AVG
Efficiency
resulting in sales per employee of £154.8k, this is less efficient (£279.5k)
£154.8k - Fujifilm Diosynth Biotechnologies Uk Limited
£279.5k - Industry AVG
Debtor Days
it gets paid by customers after 65 days, this is later than average (53 days)
65 days - Fujifilm Diosynth Biotechnologies Uk Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 18 days, this is quicker than average (44 days)
18 days - Fujifilm Diosynth Biotechnologies Uk Limited
44 days - Industry AVG
Stock Days
it holds stock equivalent to 95 days, this is in line with average (83 days)
95 days - Fujifilm Diosynth Biotechnologies Uk Limited
83 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 16 weeks, this is average cash available to meet short term requirements (20 weeks)
16 weeks - Fujifilm Diosynth Biotechnologies Uk Limited
20 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 70.8%, this is a higher level of debt than the average (47.6%)
70.8% - Fujifilm Diosynth Biotechnologies Uk Limited
47.6% - Industry AVG
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED financials
Fujifilm Diosynth Biotechnologies Uk Limited's latest turnover from March 2024 is £177.7 million and the company has net assets of £201.4 million. According to their latest financial statements, Fujifilm Diosynth Biotechnologies Uk Limited has 1,148 employees and maintains cash reserves of £25.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 177,700,000 | 147,100,000 | 145,200,000 | 118,700,000 | 114,200,000 | 125,900,000 | 81,400,000 | 76,200,000 | 55,500,000 | 46,800,000 | 46,300,000 | 48,100,000 | 42,300,000 | 64,500,000 | 44,400,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 153,800,000 | 130,900,000 | 107,000,000 | 100,000,000 | 71,100,000 | 83,300,000 | 57,700,000 | 52,800,000 | 38,200,000 | 41,400,000 | 37,900,000 | 39,700,000 | 41,800,000 | 29,000,000 | 30,500,000 |
| Gross Profit | 23,900,000 | 16,200,000 | 38,200,000 | 18,700,000 | 43,100,000 | 42,600,000 | 23,700,000 | 23,400,000 | 17,300,000 | 5,400,000 | 8,400,000 | 8,400,000 | 500,000 | 35,500,000 | 13,900,000 |
| Admin Expenses | 20,100,000 | 15,300,000 | 16,700,000 | 5,600,000 | 20,100,000 | 20,500,000 | 15,900,000 | 1,100,000 | 11,200,000 | 7,500,000 | 12,100,000 | 12,000,000 | 18,800,000 | 19,800,000 | 14,500,000 |
| Operating Profit | 3,800,000 | 900,000 | 21,500,000 | 13,100,000 | 23,000,000 | 22,100,000 | 7,800,000 | 22,300,000 | 6,100,000 | -2,100,000 | -3,700,000 | -3,600,000 | -18,300,000 | 15,700,000 | -600,000 |
| Interest Payable | 800,000 | 3,000,000 | 700,000 | 400,000 | 400,000 | 100,000 | 200,000 | 200,000 | 300,000 | 300,000 | 6,500,000 | 6,000,000 | 7,500,000 | 5,700,000 | 6,300,000 |
| Interest Receivable | 3,100,000 | 2,200,000 | 1,400,000 | 1,700,000 | 200,000 | 100,000 | 100,000 | 8,200,000 | 8,100,000 | 9,400,000 | 6,400,000 | 4,800,000 | |||
| Pre-Tax Profit | 6,100,000 | 100,000 | 22,200,000 | 14,400,000 | 22,800,000 | 22,100,000 | 7,700,000 | 22,100,000 | 6,100,000 | -2,400,000 | -2,000,000 | -1,500,000 | -16,400,000 | 15,400,000 | -2,700,000 |
| Tax | 5,200,000 | 800,000 | -3,700,000 | -2,900,000 | -2,400,000 | -1,700,000 | 5,800,000 | 2,800,000 | 1,600,000 | 700,000 | 200,000 | -1,500,000 | -1,200,000 | 2,300,000 | -3,400,000 |
| Profit After Tax | 11,300,000 | 900,000 | 18,500,000 | 11,500,000 | 20,400,000 | 20,400,000 | 13,500,000 | 24,900,000 | 7,700,000 | -1,700,000 | -1,800,000 | -3,000,000 | -17,600,000 | 17,700,000 | -6,100,000 |
| Dividends Paid | |||||||||||||||
| Retained Profit | 11,300,000 | 900,000 | 18,500,000 | 11,500,000 | 20,400,000 | 20,400,000 | 13,500,000 | 24,900,000 | 7,700,000 | -1,700,000 | -1,800,000 | -3,000,000 | -17,600,000 | 17,700,000 | -6,100,000 |
| Employee Costs | 65,100,000 | 64,300,000 | 54,800,000 | 44,900,000 | 38,800,000 | 32,900,000 | 27,800,000 | 12,200,000 | 25,100,000 | 22,700,000 | 23,200,000 | 22,900,000 | 30,200,000 | 22,900,000 | 21,800,000 |
| Number Of Employees | 1,148 | 1,184 | 1,002 | 820 | 732 | 653 | 557 | 502 | 479 | 491 | 496 | 471 | 449 | 469 | 474 |
| EBITDA* | 21,000,000 | 14,000,000 | 33,600,000 | 22,800,000 | 31,900,000 | 28,800,000 | 13,700,000 | 27,500,000 | 10,900,000 | 3,800,000 | 1,500,000 | 1,900,000 | -11,500,000 | 21,400,000 | 5,700,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 465,800,000 | 300,800,000 | 178,500,000 | 112,700,000 | 78,200,000 | 67,700,000 | 59,800,000 | 52,300,000 | 47,200,000 | 46,500,000 | 46,400,000 | 41,300,000 | 33,400,000 | 32,700,000 | 36,400,000 |
| Intangible Assets | 25,500,000 | 25,300,000 | 14,600,000 | 17,600,000 | 15,600,000 | 15,600,000 | 14,500,000 | 13,900,000 | 13,200,000 | 13,200,000 | 13,200,000 | 14,800,000 | 16,500,000 | 18,700,000 | 20,400,000 |
| Investments & Other | 52,500,000 | 55,100,000 | 77,300,000 | 67,200,000 | 69,700,000 | 59,400,000 | 66,900,000 | 58,300,000 | 41,200,000 | 34,700,000 | 10,900,000 | 8,800,000 | 11,000,000 | 11,700,000 | 5,300,000 |
| Debtors (Due After 1 year) | 1,100,000 | 2,800,000 | 5,300,000 | ||||||||||||
| Total Fixed Assets | 543,800,000 | 381,200,000 | 270,400,000 | 197,500,000 | 164,600,000 | 145,500,000 | 146,500,000 | 124,500,000 | 101,600,000 | 94,400,000 | 70,500,000 | 64,900,000 | 60,900,000 | 63,100,000 | 62,100,000 |
| Stock & work in progress | 40,400,000 | 52,700,000 | 35,600,000 | 22,500,000 | 20,700,000 | 20,400,000 | 18,700,000 | 14,400,000 | 13,000,000 | 9,000,000 | 10,000,000 | 6,700,000 | 7,900,000 | 6,200,000 | 10,000,000 |
| Trade Debtors | 32,100,000 | 23,800,000 | 39,100,000 | 23,900,000 | 40,600,000 | 17,500,000 | 14,200,000 | 17,800,000 | 9,500,000 | 6,700,000 | 9,700,000 | 8,200,000 | 10,000,000 | 5,500,000 | 9,500,000 |
| Group Debtors | 2,400,000 | 5,300,000 | 2,200,000 | 2,000,000 | 1,900,000 | 2,600,000 | 900,000 | 200,000 | 800,000 | 600,000 | 900,000 | 2,200,000 | 21,600,000 | 300,000 | |
| Misc Debtors | 45,200,000 | 40,600,000 | 34,100,000 | 20,200,000 | 17,500,000 | 18,000,000 | 9,700,000 | 10,100,000 | 6,400,000 | 5,100,000 | 4,000,000 | 5,200,000 | 5,200,000 | 5,200,000 | 2,500,000 |
| Cash | 25,300,000 | 2,300,000 | 2,500,000 | 48,600,000 | 20,900,000 | 23,100,000 | 8,200,000 | 16,000,000 | 8,600,000 | 3,800,000 | 2,200,000 | 7,400,000 | 6,000,000 | 10,600,000 | 7,100,000 |
| misc current assets | |||||||||||||||
| total current assets | 145,400,000 | 124,700,000 | 113,500,000 | 117,200,000 | 101,600,000 | 81,600,000 | 51,700,000 | 58,500,000 | 38,300,000 | 25,200,000 | 26,800,000 | 29,700,000 | 29,100,000 | 49,100,000 | 29,400,000 |
| total assets | 689,200,000 | 505,900,000 | 383,900,000 | 314,700,000 | 266,200,000 | 227,100,000 | 198,200,000 | 183,000,000 | 139,900,000 | 119,600,000 | 97,300,000 | 94,600,000 | 90,000,000 | 112,200,000 | 91,500,000 |
| Bank overdraft | 7,200,000 | 2,500,000 | 2,000,000 | ||||||||||||
| Bank loan | 4,200,000 | ||||||||||||||
| Trade Creditors | 7,900,000 | 6,700,000 | 7,500,000 | 6,400,000 | 7,600,000 | 8,100,000 | 7,000,000 | 6,900,000 | 5,100,000 | 3,400,000 | 4,000,000 | 4,500,000 | 3,300,000 | 2,100,000 | 4,600,000 |
| Group/Directors Accounts | 3,500,000 | 1,900,000 | 1,000,000 | 1,100,000 | 2,100,000 | 1,900,000 | 12,900,000 | 300,000 | 9,100,000 | 3,000,000 | 3,000,000 | 400,000 | 6,100,000 | 200,000 | |
| other short term finances | 4,000,000 | 6,000,000 | 4,000,000 | 700,000 | |||||||||||
| hp & lease commitments | 3,600,000 | 3,100,000 | 2,700,000 | 1,400,000 | 1,700,000 | ||||||||||
| other current liabilities | 64,100,000 | 99,800,000 | 125,800,000 | 99,100,000 | 47,300,000 | 65,100,000 | 37,400,000 | 41,400,000 | 31,600,000 | 22,300,000 | 16,200,000 | 17,100,000 | 15,400,000 | 11,700,000 | 13,300,000 |
| total current liabilities | 79,100,000 | 118,700,000 | 139,500,000 | 108,000,000 | 58,700,000 | 75,100,000 | 57,300,000 | 52,800,000 | 49,800,000 | 36,700,000 | 27,200,000 | 22,300,000 | 19,100,000 | 19,900,000 | 18,100,000 |
| loans | 380,000,000 | 170,000,000 | 12,800,000 | 1,600,000 | 5,600,000 | 9,500,000 | 9,300,000 | 57,800,000 | |||||||
| hp & lease commitments | 5,600,000 | 8,500,000 | 10,400,000 | 4,300,000 | 2,800,000 | ||||||||||
| Accruals and Deferred Income | 21,000,000 | 13,700,000 | 22,800,000 | 12,900,000 | 25,700,000 | 1,500,000 | 4,800,000 | 1,900,000 | 200,000 | 1,400,000 | 1,500,000 | 1,200,000 | 1,000,000 | 1,800,000 | |
| other liabilities | 2,100,000 | 2,300,000 | 2,300,000 | 2,500,000 | 700,000 | 400,000 | 800,000 | 1,100,000 | 1,500,000 | ||||||
| provisions | 6,100,000 | 5,800,000 | 500,000 | ||||||||||||
| total long term liabilities | 408,700,000 | 194,500,000 | 35,500,000 | 19,700,000 | 29,200,000 | 1,900,000 | 4,800,000 | 14,700,000 | 8,700,000 | 12,500,000 | 10,900,000 | 10,800,000 | 1,200,000 | 1,000,000 | 61,600,000 |
| total liabilities | 487,800,000 | 313,200,000 | 175,000,000 | 127,700,000 | 87,900,000 | 77,000,000 | 62,100,000 | 67,500,000 | 58,500,000 | 49,200,000 | 38,100,000 | 33,100,000 | 20,300,000 | 20,900,000 | 79,700,000 |
| net assets | 201,400,000 | 192,700,000 | 208,900,000 | 187,000,000 | 178,300,000 | 150,100,000 | 136,100,000 | 115,500,000 | 81,400,000 | 70,400,000 | 59,200,000 | 61,500,000 | 69,700,000 | 91,300,000 | 11,800,000 |
| total shareholders funds | 201,400,000 | 192,700,000 | 208,900,000 | 187,000,000 | 178,300,000 | 150,100,000 | 136,100,000 | 115,500,000 | 81,400,000 | 70,400,000 | 59,200,000 | 61,500,000 | 69,700,000 | 91,300,000 | 11,800,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 3,800,000 | 900,000 | 21,500,000 | 13,100,000 | 23,000,000 | 22,100,000 | 7,800,000 | 22,300,000 | 6,100,000 | -2,100,000 | -3,700,000 | -3,600,000 | -18,300,000 | 15,700,000 | -600,000 |
| Depreciation | 13,200,000 | 9,400,000 | 11,500,000 | 9,100,000 | 8,300,000 | 6,400,000 | 5,600,000 | 5,000,000 | 4,800,000 | 4,200,000 | 3,600,000 | 3,800,000 | 4,600,000 | 4,000,000 | 4,600,000 |
| Amortisation | 4,000,000 | 3,700,000 | 600,000 | 600,000 | 600,000 | 300,000 | 300,000 | 200,000 | 1,700,000 | 1,600,000 | 1,700,000 | 2,200,000 | 1,700,000 | 1,700,000 | |
| Tax | 5,200,000 | 800,000 | -3,700,000 | -2,900,000 | -2,400,000 | -1,700,000 | 5,800,000 | 2,800,000 | 1,600,000 | 700,000 | 200,000 | -1,500,000 | -1,200,000 | 2,300,000 | -3,400,000 |
| Stock | -12,300,000 | 17,100,000 | 13,100,000 | 1,800,000 | 300,000 | 1,700,000 | 4,300,000 | 1,400,000 | 4,000,000 | -1,000,000 | 3,300,000 | -1,200,000 | 7,900,000 | -3,800,000 | 10,000,000 |
| Debtors | 10,000,000 | -5,700,000 | 29,300,000 | -15,000,000 | 20,200,000 | 10,800,000 | 2,000,000 | 11,400,000 | 4,300,000 | -2,200,000 | -1,000,000 | 400,000 | 15,200,000 | 20,000,000 | 12,300,000 |
| Creditors | 1,200,000 | -800,000 | 1,100,000 | -1,200,000 | -500,000 | 1,100,000 | 100,000 | 1,800,000 | 1,700,000 | -600,000 | -500,000 | 1,200,000 | 3,300,000 | -2,500,000 | 4,600,000 |
| Accruals and Deferred Income | -28,400,000 | -35,100,000 | 36,600,000 | 39,000,000 | 6,400,000 | 24,400,000 | -1,100,000 | 11,500,000 | 9,500,000 | 4,700,000 | -1,000,000 | 2,000,000 | 16,600,000 | -2,400,000 | 15,100,000 |
| Deferred Taxes & Provisions | -6,100,000 | 300,000 | 5,800,000 | -500,000 | 500,000 | ||||||||||
| Cash flow from operations | 1,300,000 | -32,500,000 | 25,200,000 | 70,900,000 | 14,900,000 | 40,100,000 | 12,200,000 | 24,700,000 | 15,700,000 | 17,600,000 | -2,100,000 | 4,400,000 | -15,900,000 | 2,100,000 | 200,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | -4,400,000 | -9,500,000 | -10,300,000 | -5,300,000 | -1,300,000 | ||||||||||
| Change in Investments | -2,600,000 | -22,200,000 | 10,100,000 | -2,500,000 | 10,300,000 | -7,500,000 | 8,600,000 | 17,100,000 | 6,500,000 | 23,800,000 | 2,100,000 | -2,200,000 | 11,000,000 | 6,400,000 | 5,300,000 |
| cash flow from investments | -28,200,000 | -11,600,000 | -8,100,000 | -16,300,000 | -7,700,000 | ||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | -4,200,000 | 4,200,000 | |||||||||||||
| Group/Directors Accounts | 1,600,000 | 900,000 | -100,000 | -1,000,000 | 200,000 | -11,000,000 | 12,600,000 | -8,800,000 | 6,100,000 | 3,000,000 | -400,000 | 400,000 | 5,900,000 | 200,000 | |
| Other Short Term Loans | -4,000,000 | -2,000,000 | 2,000,000 | 3,300,000 | 700,000 | ||||||||||
| Long term loans | 210,000,000 | 170,000,000 | -12,800,000 | 11,200,000 | -4,000,000 | -3,900,000 | 200,000 | 9,300,000 | -57,800,000 | 57,800,000 | |||||
| Hire Purchase and Lease Commitments | -2,400,000 | -1,500,000 | 7,400,000 | 1,200,000 | 4,500,000 | ||||||||||
| other long term liabilities | -200,000 | -200,000 | 1,800,000 | 300,000 | 400,000 | -800,000 | -300,000 | 1,100,000 | -1,500,000 | 1,500,000 | |||||
| share issue | |||||||||||||||
| interest | 2,300,000 | -800,000 | 700,000 | 1,300,000 | -200,000 | -100,000 | -200,000 | -300,000 | -300,000 | 1,700,000 | 2,100,000 | 1,900,000 | 700,000 | -1,500,000 | |
| cash flow from financing | 208,700,000 | 151,500,000 | 11,200,000 | 500,000 | 12,600,000 | -17,000,000 | 2,600,000 | 10,800,000 | 2,800,000 | 11,800,000 | 7,700,000 | 6,500,000 | 89,600,000 | 9,100,000 | 75,900,000 |
| cash and cash equivalents | |||||||||||||||
| cash | 23,000,000 | -200,000 | -46,100,000 | 27,700,000 | -2,200,000 | 14,900,000 | -7,800,000 | 7,400,000 | 4,800,000 | 1,600,000 | -5,200,000 | 1,400,000 | 6,000,000 | 3,500,000 | 7,100,000 |
| overdraft | -7,200,000 | 4,700,000 | 2,500,000 | -2,000,000 | 2,000,000 | ||||||||||
| change in cash | 30,200,000 | -4,900,000 | -48,600,000 | 27,700,000 | -2,200,000 | 14,900,000 | -7,800,000 | 7,400,000 | 6,800,000 | -400,000 | -5,200,000 | 1,400,000 | 6,000,000 | 3,500,000 | 7,100,000 |
fujifilm diosynth biotechnologies uk limited Credit Report and Business Information
Fujifilm Diosynth Biotechnologies Uk Limited Competitor Analysis
Perform a competitor analysis for fujifilm diosynth biotechnologies uk limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in TS23 area or any other competitors across 12 key performance metrics.
fujifilm diosynth biotechnologies uk limited Ownership
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED group structure
Fujifilm Diosynth Biotechnologies Uk Limited has 1 subsidiary company.
Ultimate parent company
FUJIFILM HOLDINGS CORP
#0056744
FUJIFILM CORP
#0046393
2 parents
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED
05803359
1 subsidiary
fujifilm diosynth biotechnologies uk limited directors
Fujifilm Diosynth Biotechnologies Uk Limited currently has 4 directors. The longest serving directors include Mr Toshihisa Iida (Sep 2020) and Mr Yoshiki Kimura (Jun 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Toshihisa Iida | 57 years | Sep 2020 | - | Director | |
| Mr Yoshiki Kimura | 63 years | Jun 2023 | - | Director | |
| Mr Lars Petersen | 60 years | Jul 2023 | - | Director | |
| Mr Jonathan Haigh | 43 years | Jul 2023 | - | Director |
P&L
March 2024turnover
177.7m
+21%
operating profit
3.8m
+322%
gross margin
13.5%
+22.13%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
201.4m
+0.05%
total assets
689.2m
+0.36%
cash
25.3m
+10%
net assets
Total assets minus all liabilities
fujifilm diosynth biotechnologies uk limited company details
company number
05803359
Type
Private limited with Share Capital
industry
21200 - Manufacture of pharmaceutical preparations
72110 - Research and experimental development on biotechnology
incorporation date
May 2006
age
19
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
msd biologics (uk) limited (April 2011)
avecia biologics limited (March 2010)
See moreaccountant
-
auditor
KMPM LLP
address
fujifilm diosynth biotechnologie, belasis avenue, billingham, TS23 1LH
Bank
THE ROYAL BANK OF SCOTLAND PLC
Legal Advisor
-
fujifilm diosynth biotechnologies uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to fujifilm diosynth biotechnologies uk limited. Currently there are 1 open charges and 0 have been satisfied in the past.
fujifilm diosynth biotechnologies uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED. This can take several minutes, an email will notify you when this has completed.
fujifilm diosynth biotechnologies uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
